Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.45 |
| ▸ | KHK | P50053 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.36 |
| ▸ | AR | P10275 | 6/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27362042 | 0.84 | TRPV4 (0.43) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL29913745 | 0.82 | TSHR (0.42) | TRPV4ARTSHRALDH1A1 | |
| SCHEMBL14033196 | 0.79 | TRPV4 (0.39) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL13525263 | 0.79 | DHODH (0.40) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL30493379 | 0.79 | TRPV4 (0.43) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL25436881 | 0.79 | TRPV4 (0.43) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL3191461 | 0.79 | TRPV4 (0.43) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL19021947 | 0.79 | TRPV4 (0.39) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL11981507 | 0.77 | TRPV4 (0.38) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL16122316 | 0.76 | TRPV4 (0.35) | TRPV4KHKESR1ESR2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | TRPV4 1403/4885KHK 4470/4885ESR1 154/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | TRPV4 962/4885KHK 4599/4885ESR1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.